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Prevention of Varicella
Updated Recommendations of the Advisory Committee
on Immunization Practices (ACIP)
Summary
In February 1999, the Advisory Committee on Immunization Practices (ACIP)
expanded recommendations for varicella (chickenpox) vaccine to promote
wider use of the vaccine for susceptible children and adults. The updated recom-
mendations include establishing child care and school entry requirements, use
of the vaccine following exposure and for outbreak control, use of the vaccine
for some children infected with the human immunodeficiency virus (HIV), and
vaccination of adults and adolescents at high risk for exposure. These recom-
mendations also provide new information on varicella vaccine postlicensure
safety data.
INTRODUCTION
Varicella (i.e., chickenpox) is a highly contagious disease caused by the varicella
zoster virus (VZV). Varicella is usually a self-limited disease that lasts 4–5 days and
is characterized by fever, malaise, and a generalized vesicular rash typically consisting
of 250–500 lesions. Infants, adolescents, adults, and immunocompromised persons
are at higher risk for complications. Before the availability of varicella vaccine,
varicella disease was responsible for an estimated 4 million cases, 11,000 hospitaliza-
tions, and 100 deaths each year in the United States (CDC, unpublished data, 1999).
Approximately 90% of cases occurred in children. A vaccine was licensed in the
United States in 1995, and the Advisory Committee on Immunization Practices (ACIP)
issued recommendations for prevention of varicella in July 1996 (1 ).
RECOMMENDATIONS
Day Care and School Entry Requirements 
Because varicella incidence is highest among children aged 1–6 years, implement-
ing vaccination requirements for child care and school entry will have the greatest
impact on reducing disease incidence. ACIP recommends that all states require that
children entering child care facilities and elementary schools either have received
varicella vaccine or have other evidence of immunity to varicella. Other evidence of
immunity should consist of a physician’s diagnosis of varicella, a reliable history of the
disease, or serologic evidence of immunity. To prevent susceptible older children from
entering adulthood without immunity to varicella, states should also consider imple-
menting a policy that requires evidence of varicella vaccination or other evidence of
immunity for children entering middle school (or junior high school).
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Postexposure Vaccination and Outbreak Control
Data from the United States and Japan from household, hospital, and community
settings indicate that varicella vaccine is effective in preventing illness or modifying
varicella severity if used within 3 days, and possibly up to 5 days, of exposure (2–4 ).
ACIP now recommends the vaccine for use in susceptible persons following exposure
to varicella. If exposure to varicella does not cause infection, postexposure vaccina-
tion should induce protection against subsequent exposure. If the exposure results
in infection, no evidence indicates that administration of varicella vaccine during
the presymptomatic or prodromal stage of illness increases the risk for vaccine-
associated adverse events. Although postexposure use of varicella vaccine has poten-
tial applications in hospital settings, vaccination is routinely recommended for all
susceptible health-care workers and is the preferred method for preventing varicella
in health-care settings (1,5 ).
Varicella outbreaks in some settings (e.g., child care facilities, schools, institutions)
can last 3–6 months. Varicella vaccine has been used successfully by state and local
health departments and by the military for outbreak prevention and control. There-
fore, state and local health departments should consider using the vaccine for
outbreak control either by advising exposed susceptible persons to contact their
health-care providers for vaccination or by offering vaccination through the health
department. Guidelines for varicella outbreak investigation and control are available
from the National Immunization Program (NIP), CDC.
Vaccination of Persons Aged ≥13 Years at High Risk 
for Exposure or Transmission
ACIP has strengthened its recommendations for susceptible persons aged
≥13 years at high risk for exposure or transmission, including designating adolescents
and adults living in households with children as a new high-risk group. Varicella vac-
cine is recommended for susceptible persons in the following high-risk groups:
a) persons who live or work in environments where transmission of VZV is likely (e.g.,
teachers of young children, day care employees, and residents and staff members in
institutional settings), b) persons who live and work in environments where transmis-
sion can occur (e.g., college students, inmates and staff members of correctional
institutions, and military personnel), c) nonpregnant women of childbearing age,
d) adolescents and adults living in households with children, and e) international
travelers.
Vaccination of HIV-Infected Children and Other Persons
With Altered Immunity
Varicella vaccine is not licensed for use in persons who have blood dyscrasias,
leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone
marrow or lymphatic systems. The manufacturer makes free vaccine available to any
physician through a research protocol for use in patients who have acute lympho-
blastic leukemia (ALL) and who meet certain eligibility criteria (1 ). ACIP has previously
recommended that varicella vaccine should not be administered to persons with
primary or acquired immunodeficiency, including immunosuppression associated
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with acquired immunodeficiency syndrome (AIDS) or other clinical manifestations of
human immunodeficiency virus (HIV) infections, cellular immunodeficiencies,
hypogammaglobulinemia, and dysgammaglobulinemia. ACIP maintains its recom-
mendation that varicella vaccine should not be administered to persons who have
cellular immunodeficiencies, but persons with impaired humoral immunity may now
be vaccinated. In addition, some HIV-infected children may now be considered for vac-
cination. Limited data from a clinical trial in which two doses of varicella vaccine were
administered to 41 asymptomatic or mildly symptomatic HIV-infected children (CDC
class N1 or A1,* age-specific CD4+ T-lymphocyte percentage of ≥25%) (6 ) indicated
that the vaccine was immunogenic and effective (Pediatric AIDS Clinical Trial Group,
unpublished data, 1999). Because children infected with HIV are at increased risk for
morbidity from varicella and herpes zoster (i.e., shingles) compared with healthy chil-
dren, ACIP recommends that, after weighing potential risks and benefits, varicella
vaccine should be considered for asymptomatic or mildly symptomatic HIV-infected
children in CDC class N1 or A1 with age-specific CD4+ T-lymphocyte percentages of
≥25%. Eligible children should receive two doses of varicella vaccine with a 3-month
interval between doses. Because persons with impaired cellular immunity are poten-
tially at greater risk for complications after vaccination with a live vaccine, these
vaccinees should be encouraged to return for evaluation if they experience a postvac-
cination varicella-like rash. The use of varicella vaccine in other HIV-infected children
is being investigated further. Recommendations regarding use of varicella vaccine in
persons with other conditions associated with altered immunity (e.g., immunosup-
pressive therapy) or in persons receiving steroid therapy have not changed (1 ).
ADVERSE REACTIONS
Reporting of Postlicensure Adverse Events
Data on potential adverse events are available from the Vaccine Adverse Event
Reporting System (VAERS). During March 1995–July 1998, a total of 9.7 million doses
of varicella vaccine were distributed in the United States. During this time, VAERS
received 6,580 reports of adverse events, 4% of them serious. Approximately two
thirds of the reports were for children aged <10 years. The most frequently reported
adverse event was rash (rate: 37/100,000 vaccine doses distributed). Polymerase chain
reaction (PCR) analysis confirmed that most rash events occurring within 2 weeks of
vaccination were caused by wild-type virus (Merck and Company, Inc., unpublished
data, 1998). Postlicensure VAERS and vaccine manufacturer reports of serious adverse
events, without regard to causality, have included encephalitis, ataxia, erythema
multiforme, Stevens-Johnson syndrome, pneumonia, thrombocytopenia, seizures,
neuropathy, and herpes zoster (CDC, unpublished data, 1998). For serious adverse
events for which background incidence data are known, VAERS reporting rates are
lower than the rates expected after natural varicella or the background rates of disease
in the community (CDC, unpublished data, 1998). However, VAERS data are limited by
underreporting and unknown sensitivity of the reporting system, making it difficult to
*In CDC’s pediatric HIV Classification system, Class 1 is an immunologic category defined as
“no evidence of suppression.” For this ACIP recommendation, two clinical categories under
Class 1 are used — NI, defined as “no signs or symptoms,” and AI, defined as “mild signs or
symptoms.”
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compare adverse event rates following vaccination reported to VAERS with those
from complications following natural disease. Nevertheless, the magnitude of these
differences makes it likely that serious adverse events following vaccination occur at
a substantially lower rate than following natural disease. In rare cases, a causal rela-
tionship between the varicella vaccine and a serious adverse event has been
confirmed (e.g., pneumonia in an immunocompromised child or herpes zoster). In
some cases, wild-type VZV or other causal organisms have been identified. However,
in most cases, data are insufficient to determine a causal association. Of the 14 deaths
reported to VAERS, eight had definite other explanations for death, three had other
plausible explanations for death, and three had insufficient information to determine
causality. One death from natural varicella occurred in a child aged 9 years who died
from complications of wild-type VZV 20 months after vaccination. 
Development of Herpes Zoster
The VAERS rate of herpes zoster after varicella vaccination was 2.6/100,000 vaccine
doses distributed (CDC, unpublished data, 1998). The incidence of herpes zoster after
natural varicella infection among healthy children aged <20 years is 68/100,000 person
years (7 ) and, for all ages, 215/100,000 person years (8 ). However, these rates should
be compared cautiously because the latter rates are based on populations monitored
for longer time periods than were the vaccinees. For PCR-confirmed herpes zoster
cases, the range of onset was 25–722 days after vaccination (Merck and Company,
Inc., unpublished data, 1998). Cases of herpes zoster have been confirmed by PCR to
be caused by both vaccine virus and wild-type virus, suggesting that some herpes
zoster cases in vaccinees might result from antecedent natural varicella infection
(Merck and Company, Inc., unpublished data, 1998) (9 ).
Transmission of Vaccine Virus 
Transmission of the vaccine virus is rare and has been documented in immuno-
competent persons by PCR analysis on only three occasions out of 15 million doses of
varicella vaccine distributed. All three cases resulted in mild disease without compli-
cations. In one case, a child aged 12 months transmitted the vaccine virus to his
pregnant mother (10 ). The mother elected to terminate the pregnancy, and fetal tissue
tested by PCR was negative for varicella vaccine virus. The two other documented
cases involved transmission from healthy children aged 1 year to a healthy sibling
aged 4 1/2 months and a healthy father, respectively. Secondary transmission has not
been documented in the absence of a vesicular rash postvaccination.
CONCLUSION
This report updates previous ACIP recommendations for the prevention of
varicella. Implementing state requirements that children entering day care facilities
and schools either have received varicella vaccine or have evidence of immunity will
increase vaccine coverage. Vaccination is now recommended for outbreak control
and postexposure, and the vaccine is now available to children with humoral
immunodeficiencies and selected children with HIV infection (i.e., in CDC Class N1 or
A1, with age-specific CD4+ T-lymphocyte percentages of ≥25%). Recommendations
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for adult vaccination have been strengthened for persons at high risk for exposure and
now include adolescents and adults who live in households with children.
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